aim of this overview is to map, synthesise and assess the reliability of evidence generated from these 52 systematic reviews of the effectiveness of CBT across all health conditions, patient groups and settings.
53
Methods and analysis: We will run our search strategy, to identify systematic reviews of CBT, within Database 54 of Abstracts of Reviews of Effects, the Cochrane Library of Systematic Reviews, MEDLINE, EMBASE, PsycInfo, 55 CINAHL, Child Development and Adolescent Studies and OpenGrey between January 1992 and 25 th April 2018.
56
Independent reviewers will sift, perform data extraction in duplicate and assess the quality of the reviews 57 using the Assessing the Methodological Quality of Systematic Reviews (version. 
62
Ethics and dissemination: Ethical approval is not required as this is an overview of published systematic 63 reviews. We plan to publish results in peer reviewed journals, present at international and national academic,
64
clinical and patient conferences.
65
Registration details:
66
Our protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 67 17 th April 2018 (registration number: CRD42017078690).
69
Strengths and limitations of this study
70
• A strength of this study is that it is the only up to date overview of systematic reviews examining 
73
• Another strength is that our method allows us to map the available evidence and develop a 74 framework to suggest where evidence can be generalised to and from.
75
• The main weakness is that we will only include systematic reviews which explicitly state, "Cognitive 76 behavioural therapy" (including all synonyms) in their abstract, title or keywords. This excludes 77 broader reviews which encapsulate the CBT within "psychological interventions."
78
• Another weakness is that, we are reliant on the information provided in the systematic reviews 79 therefore we might omit RCTs if they are not included in the reviews we synthesis. 
99
The effectiveness of CBT has been evaluated with randomised control trials (RCTs) , which have been 100 synthesised into systematic reviews across numerous physical and mental health problems from 101 schizophrenia 4 to low back pain 5 . We recognised some consistency across the CBT systematic reviews e.g.
102
improving symptoms of insomnia in adults with various health problems 6 
109
This overview will explore the effects of CBT across all health problems, in all populations and in all settings.
110
The primary outcome will be Health Related Quality of Life (HRQL) with the aim of capturing, to some degree, will not be involved in any of the data extraction or quality assessment to ensure no undue influence.
139

Methods
140
We shall perform two stages within this overview. Stage one is to identify all the available systematic reviews 141 of CBT, which include RCT evidence then to map the available evidence along with a quality assessment of the 142 included reviews. The second stage will be to meaningfully synthesise the evidence by common outcomes 143 across health problems and to specifically examine the comparative effectiveness of high and low intensity 144 CBT.
145
Stage one: Mapping the evidence
146
This stage will detail how we will identify and select the systematic reviews for inclusion in order to generate a 147 comprehensive map of the evidence.
148
Eligibility criteria
149
To be included in the evidence map and overview of systematic reviews, studies must meet the following 150 criteria:
151 152
Type of studies: We will include systematic reviews of randomised control trials (RCTs) which evaluate the 153 effects of CBT. We will include systematic reviews which include both randomised and non-randomised trials 154 so long as the review has summarised the RCT evidence independently.
156
To be included, systematic reviews must fulfil a minimum of 4 methodological criteria as defined by 
164
Type of participants: We will include systematic reviews of RCTs, which include data from all age groups and 165 any gender. We will include all health problems recognised within the ICD-11.
167
Setting: We will include systematic reviews of RCTs that have been conducted in any context or country.
169
Intervention: We will only include systematic reviews where Cognitive Behavioural Therapy (or other CBT 170 synonyms) has been explicitly reported in the review title, abstract or key words. We will include all formats of
171
CBT. We will classify if the review's RCTs are employing high or low intensity CBT as defined by Roth and
172
Pilling's Department of Health report 3 . High intensity CBT refers to face to face therapy with a relatively 173 specialist trained CBT therapist and low intensity is all other types of CBT (blended care, guided self-help,
174
internet-based, structured exercises or brief interventions).
176
Comparator: We will include systematic reviews if they explore comparisons of CBT to either: 1) Active: a non-
177
CBT comparator intervention 2) No Active: no intervention, waitlist control, placebo or treatment as usual or 178 (3) Another format of CBT (e.g. computerised CBT versus face to face). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y Outcomes: We will include systematic reviews which report information on at least one of the following 181 patient or other reported outcomes: (1) HRQL (2) Psychological (3) Physical/physiological. We will include 182 reviews with short (<12 months) and long term (>=12 months) outcomes.
180
184
Restrictions: We will include only reviews that are published/available in the English language due to the 185 limited study timescale. We shall only include reviews which were published after 1992.
186
Information Sources
187
Our method of identifying systematic reviews will be conducted according to the principles of the Cochrane
188
Handbook for Systematic Reviews of Interventions 14 and recommendations for conducting Overviews of 189 Systematic Reviews 15 .
191
The search strategy will be run across . The full-text of reviews shortlisted for full text analysis will also be uploaded to 215
Covidence. We shall perform data extraction using Microsoft Excel.
216
Selection process
217
Two reviewers will independently screen titles and abstracts using the abstract screening questionnaire which 218 is based on the eligibility criteria. We will obtain full-text reports of those reviews selected for inclusion or for 
223
Conference abstract with insufficient data. We will not contact authors for clarification. We will resolve any 224 disagreements regarding the inclusion or exclusion of individual reviews by discussion with a third reviewer.
226
The search process and study identification will be documented in a figure as recommended by PRISMA 227 statement 20 . This will result in a final list of included and excluded systematic reviews along with reasons for 228 exclusion. This process will not be blinded so all reviewers will be able to see the authors and their affiliated 229 institutions. 
230
270
Mapping by review details: The availability of the evidence will also be described by the following: (1) severity
271
(mild, moderate, severe), (2) who (children, adults, older adults), (3) how (CBT intervention details), (4) when
272
(prevention, standard treatment, relapse prevention etc), (5) where (primary, secondary, hospital setting), (6) 273 psychological outcomes, (7) physiological outcomes and (8) confidence' (amber) and 'critically low' (red) 23 . This aims to give some direction as to the level of confidence.
278
Stage two
279
From the evidence maps populated in stage one we shall focus on the common outcomes examined within the 280 included reviews. Stage two is to identify systematic reviews which we can synthesis to identify generic and 281 specific effects of CBT across and within health problems. 
283
303
Where available we will descriptively report the descriptions of mechanisms of action, patient satisfaction, 304 adverse events and economic outcomes.
305
306
We shall group all of the reviews which include a HRQoL outcome together. From these we shall identify those 307 which have performed a meta-analysis of the data. These reviews shall be grouped by their ICD-11 
321
The selected reviews will be examined to identify those with moderate clinical, design and statistical 322 homogeneity. Statistical heterogeneity in treatment effect estimates between health problems will be 323 explored using the I 2 statistic (moderate to low heterogeneity I 2 less than 75%); clinical heterogeneity will be 324 explored through discussion with the ECG; and design heterogeneity explored using AMSTAR-2 scores.
326
We shall repeat this process for all reviews which include a depression outcome and an anxiety outcome. We 327 will list all the physical/physiological outcomes which have been examined across all of our included reviews.
328
The outcome which is the most common will be identified as the fourth outcome for selection.
330
Synthesis
331
We will synthesise these reviews and provide pooled treatment effects for all reviews which include a (1)
332
HRQoL outcome, (2) Depression outcome (3) anxiety outcome and (4) This formal quantitative data synthesis will be undertaken using a two-step frequentist approach to a PMA.
336
This method provides a single pooled estimate of the treatment effect along with estimates of degree of 337 heterogeneity between reviews. This allows for both between study variability within the health problem (if 338 random effects meta-analysis was used in the original indication review) and between health problem 339 variability (using random effects), but does assume exchangeability of treatment effects.
341
We will perform this process for the outcomes of HRQoL, depression, anxiety and the most common physical/ 342 physiological outcome. As we have collected other psychological and physical/physiological outcomes we will 343 remain flexible and will consider additional synthesis suggested by the ECG.
345
Sub-group analysis:
346
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Strengths and limitations of this study
69
72
• Another strength is that our method allows us to map the available evidence and develop a 73 framework to suggest where evidence can be generalised to and from.
74
• The main weakness is that we will only include systematic reviews which explicitly state, "Cognitive 
77
• Another weakness is that, we are reliant on the information provided in the systematic reviews 78 therefore we might omit RCTs if they are not included in the reviews we synthesis. 
107
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137
Methods
138
We shall perform two stages within this overview. Stage one is to identify all the available systematic reviews 139 of CBT, which include RCT evidence then to map the available evidence along with a quality assessment of the 140 included reviews. The second stage will be to meaningfully synthesise the evidence by common outcomes 
144
This stage will detail how we will identify and select the systematic reviews for inclusion in order to generate a 145 comprehensive map of the evidence.
146
147
To be included in the evidence map and overview of systematic reviews, studies must meet the following 148 criteria:
149 150
Type of studies: We will include systematic reviews of randomised control trials (RCTs) which evaluate the 151 effects of CBT. We will include systematic reviews which include both randomised and non-randomised trials 152 so long as the review has summarised the RCT evidence independently.
154
To be included, systematic reviews must fulfil a minimum of 4 methodological criteria as defined by the Centre 
162
Type of participants: We will include systematic reviews of RCTs, which include data from all age groups and 163 any gender. We will include all health problems recognised within the ICD-11.
165
167
Intervention: We will only include systematic reviews where Cognitive Behavioural Therapy (or other CBT 168 synonyms) has been explicitly reported in the review title, abstract or key words. We will include all formats of 169 CBT. We will classify if the review's RCTs are employing high or low intensity CBT as defined by Roth and 170
Pilling's Department of Health report 3 . High intensity CBT refers to face to face therapy with a relatively 171 specialist trained CBT therapist and low intensity is all other types of CBT (blended care, guided self-help,
172
174
175
CBT comparator intervention 2) No Active: no intervention, waitlist control, placebo or treatment as usual or 176 (3) Another format of CBT (e.g. computerised CBT versus face to face).
178
Outcomes: We will include systematic reviews which report information on at least one of the following 179 patient or other reported outcomes: (1) HRQL (2) Psychological (3) Physical/physiological. We will include 180 reviews with short (<12 months) and long term (>=12 months) outcomes.
182
Restrictions: We will include only reviews that are published/available in the English language due to the 183 limited study timescale. We shall only include reviews which were published after 1992.
184
185
Our method of identifying systematic reviews will be conducted according to the principles of the Cochrane 
200
Our scoping work has identified that the earliest published review of CBT which has not been superseded is 201 1992 18 . This year also saw the advent of the Cochrane Collaboration, which implements high quality systematic 202 reviews of RCTs across health care. Therefore, we restrict our search to the last 26 years.
203
Our search strategy picked up 36/36 sensitivity check papers. The strategy was adapted and checked for use 204 across each of our selected databases. Our MEDLINE search strategy is attached in Appendix A.
206
We will perform an update search (April 2019) to check for any additional systematic reviews which have been 207 published in the intervening year. We will also search PROSPERO, ClinicalTrials.gov and Clinical Trials Registry
208
Platform (ICTRP) to identify any on-going systematic reviews and clinical trials to inform our discussion.
209
Study records
210
Data management
211
Search results will be exported into Endnote for de-duplication and then exported into Covidence, as 212 recommended by Cochrane
19
. The full-text of reviews shortlisted for full text analysis will also be uploaded to 213
214
215
Two reviewers will independently screen titles and abstracts using the abstract screening questionnaire which 216 is based on the eligibility criteria. We will obtain full-text reports of those reviews selected for inclusion or for 
221
Conference abstract with insufficient data. We will not contact authors for clarification. We will resolve any 222 disagreements regarding the inclusion or exclusion of individual reviews by discussion with a third reviewer.
224
The search process and study identification will be documented in a figure as recommended by PRISMA 225 statement 20 . This will result in a final list of included and excluded systematic reviews along with reasons for 226 exclusion. This process will not be blinded so all reviewers will be able to see the authors and their affiliated 227 institutions.
228
Data collection process
229
We developed a bespoke data extraction form with the ECG. Two reviewers will pilot the form on the first 18 230 reviews from the sensitivity check for the search strategy and revise accordingly. Two reviewers will extract 231 the review data items and perform the AMSTAR-2 quality assessment. A third reviewer will compare the 232 duplicate extractions and the anomalies will be discussed until a decision is reached. 
268
269
270
(prevention, standard treatment, relapse prevention etc), (5) where (primary, secondary, hospital setting), (6) 271 psychological outcomes, (7) physiological outcomes and (8) 
320
The selected reviews will be examined to identify those with moderate clinical, design and statistical 321 homogeneity. Statistical heterogeneity in treatment effect estimates between health problems will be 322 explored using the I 2 statistic (moderate to low heterogeneity I 2 less than 75%); clinical heterogeneity will be 323 explored through discussion with the ECG; and design heterogeneity explored using AMSTAR-2 scores.
325
We shall repeat this process for all reviews which include a depression outcome, an anxiety outcome and a 326 psychosis outcome. We will list all the physical/physiological outcomes which have been examined across all of 327 our included reviews. The outcome which is the most common will be identified as the fifth outcome for 328 selection.
330
Synthesis
331
332
HRQoL outcome, (2) Depression outcome (3) anxiety outcome (4) psychosis outcome and (5) most common 333 physical/physiological outcome.
335
This formal quantitative data synthesis will be undertaken using a two-step frequentist approach to a PMA.
336
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